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Abstract Improvement of cancer therapy by introducing new
concepts is still urgent even though there have been major
advancements lately. Immunotherapy is well on the way to
becoming an established tool in the cancer treatment armory.
It seems that a combination of (1) activation of immune
effector cells and selective targeting of them to tumors and
(2) the inhibition of immune suppression often induced by the
tumor itself are necessary to achieve the therapeutic goal. The
immunotoxin naptumomab estafenatox was developed in an
effort to activate and target the patient’s own T cells to their
tumor, by fusing a superantigen (SAg) variant that activates
T lymphocytes to the Fab moiety of a tumor-reactive mono-
clonal antibody. Naptumomab estafenatox targets the 5T4
tumor antigen, a 72-kDa oncofetal trophoblast protein
expressed on many carcinomas, including renal cell carcino-
ma. The therapeutic effect is associated with activation of
SAg-binding T cells. The SAg-binding T lymphocytes ex-
pand, differentiate to effector cells, and infiltrate the tumor.
The therapeutic efficacy is most likely related to the dual
mechanism of tumor cell killing: (1) direct lysis by cytotoxic
T lymphocytes of tumor cells expressing the antigen recog-
nized by the antibody moiety of the fusion protein and (2)
secretion of cytokines eliminating antigen-negative tumor cell
variants. Naptumomab estafenatox has been clinically tested
in a range of solid tumors with focus on renal cell carcinoma.
This review looks at the clinical experience with the new
immunotoxin and its potential.
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Naptumomab estafenatox
Introduction
The therapeutic landscape for many malignancies is rapidly
changing. Among the important developments of recent years
is the rise of therapies activating or releasing the power of
immunological mechanisms. Older immune therapies against
solid malignancies have proved toxic and only modestly
active in clinical practice. However, a deeper understanding
of tumor immunology has led to recent successes, including
the FDA approval of sipuleucel-T to treat prostate cancer as
well as ipilimumab to treat malignant melanoma. Although
certain cancers have been identified as being susceptible to
immune-based interventions, new evidence indicates that im-
munotherapies might become a general therapeutic tool in the
treatment of cancer. It seems that a combination of (1) activa-
tion of immune effector cells and selective targeting of them to
tumors and (2) the inhibition of immune suppression often
induced by the tumor itself are necessary to achieve the
therapeutic goal. In an effort to activate and target the patient’s
own T cells to their tumor, the immunotoxin naptumomab
estafenatox was developed and has so far been clinically
tested in a range of solid tumors with focus on renal cell
carcinoma. This report provides an overview of the clinical
experience and the status of development of the naptumomab
estafenatox (ABR-217620; ANYARA).
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The tumor-targeted superantigen (TTS) concept uses a unique
approach to target large numbers of T cells to tumors
[1, 2•, 3] and utilizes a distinct type of immunotoxin.
T lymphocytes are very effective in eliminating some
experimental tumors. However, in humans, tumor-
specific T cells often occur in low numbers or may be
suppressed. Therefore, their numbers are insufficient to
interfere with established growing cancer. In the TTS
concept, bacterial superantigens (SAgs), the most potent
known activators of human T cells, are used to activate and
recruit large numbers of T cells to the targeted tumors.
The wild-type SAg staphylococcal enterotoxin A (SEA)
binds effectively to MHC class II+ accessory cells and acti-
vates both CD4+ and CD8+ T cells [4, 5]. MHC class II+ cells
are killed by cytotoxic T lymphocytes (CTLs) when targeted
by SEA [6–9]. A tumor-specific SAg is created by fusing the
SAg to the Fab moiety of a tumor-reactive monoclonal anti-
body (mAb). Fab–SAg fusion proteins have been successfully
used to cure mice with established experimental tumors. The
therapeutic effect was associated throughout the tumor with a
massive infiltration of T cells which actively produced
tumoricidal cytokines such as tumor necrosis factor α
and interferon (IFN)-γ. The therapeutic efficacy is most
likely related to the dual mechanism of tumor cell
killing: direct lysis of tumor cells expressing the antigen
recognized by the antibody moiety of the fusion protein
and secretion of cytokines eliminating antigen-negative
tumor cell variants (Fig. 1).
The TTS therapeutic proteins, including naptumomab
estafenatox, are typically used in cycles of four to five once-
daily intravenous injections. In the first phase of a cycle, the
T lymphocytes are activated and differentiate into effector
cells, which later in the cycle localize to the tumor andmediate
their antitumor functions (Fig. 1). This treatment schedule can
be repeated and is easily combined with other anticancer drug
modalities.
The early clinical trials with TTS were performed using
wild-type SEA as the T-cell activator [10, 11]. However, this
fusion protein (nacolomab tafenatox) was associated with a
most potent T-cell activation and therefore it was necessary to
give the intravenous doses at only a few nanograms per
kilogram to avoid unacceptable toxicity. In addition, the dose
had to be individualized on the basis of preformed anti-SAg
(anti-SEA) antibodies. Wild-type SAgs bind to MHC class II
cell membrane proteins, and the complexes subsequently bind
to T-cell receptors (TCRs) containing certain Vβ sequences.
After proliferation and differentiation, these T lymphocytes
infiltrate the tumor tissue and are activated in the tumor owing
to TCR binding to the SAgs of the TTS protein. The activated
T cells produce cytokines, mainly of the Th1 type, e.g., IL-2
and IFN-γ, and perform direct perforin-dependent tumor kill-
ing. To achievemaximal targeted antitumor effects, a balanced
relationship between the binding affinities of the three func-
tional binding sites in the TTS is required. The desire to mimic
the T-effector cell (e.g., the CTL) binding via its TCR to the
MHC/tumor peptide target on a tumor target cell drove the
development of naptumomab estafenatox, which showed dis-
tinct characteristics regarding binding to the tumor antigen
(5T4), the TCR, and the MHC class II proteins [12••, 13]. It is
currently hypothesized that an optimal TTS should have very
high affinity for the tumor antigen, low affinity for TCR, and
very low affinity for MHC class II proteins. Naptumomab
Fig. 1 a Mechanism of action of naptumomab estafenatox (Nap). b
Immune/drug functions during a naptumomab estafenatox (Nap) treat-
ment cycle. c Different fusion proteins. The tumor-targeted superantigens
are naptumomab estafenatox, anatumomab mafenatox, nacolomab
tafenatox, and C215–staphylococcal enterotoxin A (SEA).CTL cytotoxic
T lymphocyte, IFN interferon, TAA tumor-associated antigen, TCR T-cell
receptor, TNF tumor necrosis factor
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estafenatox binds to the 5T4 tumor antigen with KD of ap-
proximately 1 nM. SEA/E-120, the SAg part of naptumomab
estafenatox, has been characterized in detail and has been
found to primarily bind and operate through TCR TRBV7-9
with a binding constant of 0.48 μM and an affinity for MHC
class II proteins of 51 μM.
A fusion protein consisting of the Fab moiety of the mAb
5T4 fused to SEA with a point mutation decreasing MHC
class II protein binding (associated with decreased toxicity),
anatumomab mafenatox [14], a predecessor of naptumomab
estafenatox, was investigated in clinical phase 1 and phase 2
trials with encouraging results [15, 16•]. However, this fusion
protein was also associated with some of the drawbacks seen
with nacolomab tafenatox, particularly the need to give low
doses as well as individualized dosing based on preformed
anti-SAg (anti-SEA) antibodies. The novel genetically modi-
fied immunotoxin naptumomab estafenatox displays strong
affinity for the 5T4 tumor antigen, on the order of 1 nM, and is
approximately 50 % more efficient than anatumomab
mafenatox in killing human 5T4-positive tumor cells in vitro
[12••]. Naptumomab estafenatox does induce anMHC class II
and dose dependent proliferation of human lymphocytes, but
only at 50-fold and more than 103-fold higher concentrations
than anatumomab mafenatox and nacolomab tafenatox, re-
spectively [12••]. Furthermore, preformed human anti-SAg
antibodies did not recognize the functional regions in the
SAg part of naptumomab estafenatox to the same extent
as in the predecessor construct [12••]. Thus, even
though naptumomab estafenatox has very potent antitu-
mor properties, it contains an SAg moiety without clas-
sic SAg activity. The MHC class II binding capacity is
minimal and the T-cell proliferation induced by
naptumomab estafenatox has a median effective concen-
tration more than 103 times higher than those of con-
ventional wild-type SAgs, resulting in dramatically re-
duced toxicity. Furthermore, the levels of target epitopes for
naturally occurring anti-SAg antibodies were reduced and
dosing of naptumomab estafenatox was therefore considered
to be independent of normal baseline levels of anti-SAg
antibodies.
Naptumomab estafenatox targets the 5T4 tumor antigen, a
72-kDa oncofetal trophoblast protein originally isolated from
placenta and characterized by the use of the murine IgG1mAb
5T4 [17, 18]. Expression of 5T4 antigen has been shown to
influence adhesion, cytoskeletal organization, and motility,
properties which might account for its association with poorer
clinical outcome in some cancers [19]. A general screen by
immunohistochemistry on frozen sections showed that many
different carcinomas express the 5T4 antigen [20–27]
(Table 1), and very often the 5T4 antigen levels appear to be
higher in more advanced stages of cancer. Studies have shown
a homogenous reactivity, which in most cases is moderate to
strong, in more than 95 % of non-small-cell lung cancer
(NSCLC), pancreatic cancer (PC), and renal cell cancer
(RCC). In many cases, tumor stromal reactivity has been
observed in addition to tumor cell reactivity. Outside the
placenta, 5T4 normal tissue reactivity is considered to be most
limited and there is no evidence of circulating 5T4 antigen.
Naptumomab estafenatox with the selectivity of the 5T4 mAb
has been in clinical development primarily for the indications
of NSCLC and RCC. It targets a tumor antigen highly
expressed on tumor cells, with very low expression on normal
tissue and without soluble antigen interference.
Naptumomab Estafenatox—Phase 1 Studies
Naptumomab estafenatox was developed in parallel with the
initial clinical studies with its predecessor anatumomab
mafenatox and has been evaluated in phase 1 trials in
NSCLC, PC, and RCC patients [28••, 29]. Altogether, 52
Table 1 5T4 reactivity in a variety of tumor types Cancer
Cancer Stage /Type Reactivity Conclusions
Breast Mixed 56/63 85–95 % of patients express the
5T4 antigen.





Colorectal Mixed 11/22 40–50 % of patients express the
5T4 antigen. In Dukes stage






Gastric Mixed 41/93 Approximately 50 % of patients
express the 5T4 antigen on
tumor cells. Most samples with
5T4 negative tumor cells have






NSCLC Mixed 259/261 99 % of patients express the
5T4 antigen.
Ovarian Mixed 4/7 More than 70 % of patients
express the 5T4 antigen..
For stage IV patients,






Pancreatic Mixed 23/23 100 % of patients express the
5T4 antigen.
Prostate Mixed 26/26 100 % of patients express the
5T4 antigen.
Renal Clear cell 215/222 >95 % of patients express the
5T4 antigen.Papillary 18/18
Mixed 36/37
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patients were investigated in the monotherapy (MONO) trial
and the combination therapy (COMBO) trial with docetaxel.
The primary aim was to establish the maximum tolerated dose
of naptumomab estafenatox. The secondary objectives were to
determine the safety profile, pharmacokinetic parameters, im-
munological response, and effects on tumor disease. The
MONO study was conducted in Norway, the UK, and the
USA. The main inclusion criteria were histologically or cyto-
logically confirmed disease, which was refractory to available
standard therapies. Patients had to have an Eastern
Cooperative Oncology Group performance status of 0 or 1
and life expectancy of more that 3 months. Three different
indications were investigated, consisting of 20 cases of
NSCLC, 11 cases of RCC, and eight cases of PC. The starting
dosage was 500 ng/kg/day administrated as a 5-min bolus
injection and naptumomab estafenatox was given for five
consecutive days. Six dose-limiting toxicities were recorded,
and the highest dosage investigated was 27.4 μg/kg/day.
Patients with stable disease or response were considered for
treatment with a second 5-day cycle, unless they had experi-
enced a dose-limiting toxicity. The most notable side effects
were fever, nausea, and rigors, and these were easilymanaged.
It was concluded that the side effects were not dependant on
the anti-SAg (anti-SEA/E-120) antibody titers. The recom-
mended phase 2 dosage was set at 15 μg/kg/day for patients
with RCC and 22μg/kg/day for patients with NSCLC and PC.
As part of the immune activation, increased systemic levels
of IL-2, IFN-γ, and IL-10 were observed 3 h after
naptumomab estafenatox treatment, and there was a correla-
tion between the dose and cytokine induction. We have eval-
uated the cytokine responses as a surrogate for a beneficial
pharmacologic effect [16•] in all patients from theMONO and
COMBO studies. Plasma IL-2 levels were dose-dependently
increased 3 h after injection of naptumomab estafenatox in the
first treatment cycle [28••]. RCC patients had larger increases
than NSCLC or PC patients. The IL-2 response declined in the
later parts of the treatment cycle, showing only marginally
elevated IL-2 levels on days 4 and 5. Plasma IFN-γ levels
were also dose-dependently increased 3 h after TTS injection.
The IFN-γ response declined only slightly as the treatment
cycle progressed, and unlike IL-2, high IFN-γ levels were also
recorded on days 4 and 5. Plasma IL-10 levels were dose-
dependently increased 3 h after injection of naptumomab
estafenatox and continued to increase as the treatment cycle
progressed. One may speculate that a powerful immune acti-
vation stimulates inhibitory responses, such as IL-10 produc-
tion, similar to that seen as a vigorous antivirus response is
naturally downregulated.
A mechanistically important finding was that the SAg
reactive population of T cells expressing the TCR TRBV7-9
was selectively expanded after naptumomab estafenatox treat-
ment and returned to normal levels at day 28. The anti-SAg
(anti-SEA/E-120) levels were stable or only moderately
increased in approximately 50 % of the patients after one
cycle, and human anti-mouse antibody levels were very low.
A major objective in the development of the TTS
fusion proteins has been a short systemic exposure to
provide high tumor targeting capability combined with
acceptable toxicity. The pharmacokinetics of naptumomab
estafenatox show a small volume of distribution (about
0.14 L/kg) and a low clearance (about 0.13 L/h/kg). The mean
terminal half-life was determined to be 1.4 h. No time
dependency was seen in the pharmacokinetics in the
first treatment cycle, with similar plasma concentrations
on day 1 and day 5. Furthermore, no dose dependency
in the pharmacokinetics was indicated at doses of
10 μg/kg and greater and no effect of gender or disease
indication in the pharmacokinetic parameters of
naptumomab estafenatox was seen. During the first
treatment cycle no significant effect of anti-SAg (anti-
SEA/E-120) antibody levels on pharmacokinetic param-
eters was seen .
Efficacy was analyzed by CT scan. Several patients in the
MONO study had tumor shrinkage, not amounting to formal
Response Evaluation Criteria in Solid Tumors partial re-
sponses. The median overall survival times were 15.8 months
for the NSCLC patients, 26.2 months for the RCC patients,
and 5.2 months for the PC patients. Although these studies
were not controlled and a bias in patient selection cannot be
excluded, the median overall survival for the NSCLC and
RCC patients was encouraging. It should be noted that these
early studies were performed prior to the widespread use of
antiangiogenic agents in the treatment of RCC.
An open-label dose-escalation study of naptumomab
estafenatox in combination with docetaxel (COMBO) was
conducted in Denmark, Russia, and the USA [28••]. In this
COMBO study, 13 patients with advanced NSCLC were
treated. The primary end point was to describe the side effect
profile of the combination treatment and establish the maxi-
mum tolerated dose of naptumomab estafenatox in combina-
tion with docetaxel. Secondary end points included pharma-
cokinetics, immunological responses, changes in anti-SAg
(anti-SEA/E-120) levels, and effects on tumor disease.
Patients were treated with a bolus injection of naptumomab
estafenatox in 5 min for four consecutive days followed by
75 mg/m2 docetaxel on day 5. Three weeks later this proce-
dure was repeated. Three patients received naptumomab
estafenatox at a dosage of 10 μg/kg/day, three patients re-
ceived it at a dosage of 16.5 μg/kg/day, and seven patients
received it at a dosage of 22 μg/kg/day. No synergistic toxic-
ities were observed. The best overall responses were two
patients with partial response, five patients with stable disease,
and three patients with progressive disease, and three patients
were not evaluable. Biopsy specimens were taken from two
patients on day 3 of the second cycle. In both patients tumor
5T4 expression and marked T-cell infiltration of the
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metastases were confirmed. One of these patients had a partial
response. Themedian survival for the patientswas 9.3months.
Formation of antibody against SEA/E-120 was low in these
patients. Anti-SEA/E-120 levels were compared after the first
treatment cycle in the COMBO study with those in the
MONO study, and the comparison showed that docetaxel
appeared to reduce anti-SAg antibody production when it
was given 1 day after the last injection in a treatment cycle
with naptumomab estafenatox. Since the avoidance of high-
titer neutralizing antibodies would be advantageous for
multicycle treatment with naptumomab estafenatox, combina-
tions with docetaxel or other inhibitors of anti-SAg antibody
production might be beneficial.
Naptumomab Estafenatox—Phase 2/3 Studies
and Baseline Biomarkers for RCC Patient Selection
In preclinical models, IFN-α had been shown to enhance and
sustain TTS-induced CTL activity when given in combination
[30]. This observation led to a randomized phase 2/3 trial of
naptumomab estafenatox plus IFN-α versus IFN-α conducted
in 513 patients with advanced RCC. The patients were recruit-
ed between March 2007 and May 2009 and randomized 1:1 in
an open-label study to receive naptumomab estafenatox plus
IFN-α or IFN-α: 15 μg/kg naptumomab estafenatox was given
intravenously in three cycles of four once-daily injections plus
IFN-α (9 MU subcutaneously three times weekly) or the same
dose and schedule of IFN-α monotherapy alone. The primary
end point was overall survival. The secondary end points were
progression-free survival, response rate, and safety.
The first set of results was presented at the 2013 American
Society of Clinical Oncology annual meeting [31]. Although
the primary end point of overall survival (hazard ratio (HR) of
1.08) was not reached, the secondary endpoint of progression‐
free survival showed a HR of 0.92. Exploratory endpoints of
anti‐SAg (anti‐SEA/E‐120), a biomarker for drug exposure,
and IL‐6, a biomarker for immune responsiveness, were
assessed as predictive biomarkers. In contrast to the results
of earlier studies, significantly increased baseline anti-SAg
(anti-SEA/E-120) antibody levels were detected in certain
territories. In a subgroup of patients having below median
baseline levels of anti-SAg (anti-SEA/E-120) and IL-6,
prolonged progression-free survival (HR=0.62, p =0.016)
and overall survival (HR=0.59, p =0.020) were achieved.
Naptumomab estafenatox was well tolerated. Most of the
adverse events resulting from treatment with naptumomab
estafenatox related to increased levels of cytokines and are
expected as part of the mechanism of action. Pyrexia,
vomiting, nausea, chills, and back pain were commoner after
treatment with naptumomab estafenatox.
A detailed analysis of the results is ongoing and the result
will therefore not be discussed further in this review. As
previously described, naptumomab estafenatox is a fusion
protein containing an engineered hybrid of Staphylococcus
entertoxins A and E (SEA/E-120). Although SEA/E-120 has
been engineered to express a minimum of antigenic epitopes
in the wild-type SAgs recognized by patient antibodies at the
baseline [12••], certain patients may have elevated levels
owing to cross-reactivity to previously encountered wild-
type Staphylococcus enterotoxins, e.g., through infections
from Staphylococcus aureus . The results from the phase 1
studies showed that baseline plasma anti-SAg (anti-SEA/E-
120) levels were low in most patients and indicated that the
exposure of clinically relevant doses (12 μg/kg or more) of
naptumomab estafenatox was independent of the low levels of
baseline antibodies. In the phase 2/3 study of RCC patients,
the number of patients was vastly expanded and the countries
in which they were recruited changed from the phase 1 stud-
ies. Increased baseline anti-SAg (anti-SEA/E-120) antibody
levels were detected in certain territories, predicting subopti-
mal exposure [31], which may affect drug activity and antitu-
mor efficacy. Therefore, anti-SAg (anti-SEA/E-120) seems to
be a baseline biomarker for exposure important for the selec-
tion of patients for treatment with naptumomab estafenatox.
Conclusion
Naptumomab estafenatox has therapeutic potential in tumors
expressing the 5T4 antigen. Clinical development of
naptumomab estafenatox is now focused on the identified pa-
tient subset of RCC and studies using naptumomab estafenatox
add-on treatment with established tyrosine kinase inhibitors in
the first or second line. Furthermore, as data accumulate regard-
ing the necessity of using combinations of immunotherapies to
reach full effect [32•], naptumomab estafenatox might require
themodulation of immune checkpoints with, e.g., ipilimumab or
nivolumab, for optimal activity.
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